Accurate accounting of caplacizumab cost effectiveness
George Goshua1, Vinay Prasad2, Alfred Ian Lee1
1Division of Hematology, Yale University School of Medicine, New Haven, CT, USA.
The Lancet. Haematology
|April 24, 2021
Abstract
No abstract available in PubMed .
More Related Videos
06:16Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
Published on: August 9, 2024
630
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
18.0K
